Nettoomsättningen för det tredje kvartalet uppgick till 119,6 MSEK (99,8), vilket motsvarade en orga...
Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated d...
Redeye retains its view of Hanza following a Q4 report showing a relatively solid performance in a s...
EBITA grew 37% y-o-y Sees positive signals in the Swedish project market Trading at 9x '25e EV/EBITA...
Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.
On February 11th, Eevia Health Plc (publ) (“Eevia”) announced multiple new sales orders for products...
Analyst Group inleder idag den 11:e februari 2024 analysbevakning på Hifab Group (”Hifab”, ”Koncerne...
Q4 report due on 21 February Q4e sales: EUR 47m, order intake: EUR 43m Several orders announced duri...
Tough end to 2024 Market to turn positive in '25e, according to report Re-setting expectation, '25e ...
Redeye comments on Neola Medical’s approved clinical study in Sweden, which is expected to run for a...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Stronger end to Q4 vs the PW in Dec Adj. EBITA 18% higher than guided for Estimates up slightly toda...
Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj.
Redeye comments on the Q4 report from Moberg Pharma.
Net sales SEK 537m, +3% vs ABGSCe, 0% vs Factset cons.
Redeye will likely retain its view of Hanza following a Q4 report with sales and EBITA slightly belo...
In our view, earnings will become more stable, as the company seems satisfied with its structure aft...
Revenue growth could be as high as ~50% y/y for Q4 2024E, due to a low comparison.
Q4e soft, market remains muted Lower range of targets likely Recovery postponed, '25 also slow Q4e ...
Solteq reports Q4’24 results on Thursday, February 13th.
